Skip to main content

Table 3 Response rates and proportion of patients with measured tumor shrinkage >10% in single agent placebo or best supportive care arms of randomized trials

From: Fool’s gold, lost treasures, and the randomized clinical trial

Tumor type RECIST response % % of patients with measurable tumor shrinkage >10%a
NSCLC [21] 1 NAb
NSCLC [22] <1 NA
NSCLC [91] 0.7 NA
NSCLC [92] 1 NA
Colorectal [52] 0 1
Colorectal [93] 0 NA
Colorectal [94] 0 NA
Renal cell [95] 2 NA
Renal cell [96] 0 NA
Renal cell [97] 3 NA
Renal cell [98] 0 4
Renal cell [99] 0 5.5
Hepatocellular [100] 0 9
Hepatocellular [101] 3 NA
Hepatocellular [102] 1.3 NA
Head and neck cancer [103] 0 7
Head and neck cancer [104] 1 NA
Head and neck cancer [105] 3 NA
Transitional cell [106] 0 NA
Pancreatic neuroendocrine [107] 0 7
Pancreatic neuroendocrine [112] 2 6.6
Prostate [108] 4 NA
Sarcoma [109] 0 NA
Medullary thyroid [110] 1 NA
Mesothelioma [111] 1.7 NA
  1. a. Calculated by manual measurement of published waterfall plots.
  2. b. NA = not available.